Navigation Links
A giant little step in cancer treatment opening up new therapeutic horizons
Date:2/27/2012

Barcelona, 27 February 2012. A study headed up by the Vall d'Hebron Institute of Oncology (VHIO) heralds a new horizon in the fight against cancer, opening up a parallel dimension to existing treatment options. The data, published today in the Journal of Clinical Oncology, demonstrate that by combining two drugs that had already been used on a patient in the past but had stopped working, they boost each other's efficacy and at the same time manage to break down the patient's resistance to each of them individually, presenting a third potential treatment option for clinically advanced metastatic tumours.

While this may not initially appear to be an innovation, given that combined treatments are used in cancer as a matter of course, it actually represents a radical change in the use of the existing therapeutic weaponry, an extremely practical solution and a source of hope for many patients. "The novelty factor does not lie in the combination itself, but in the combination of two drugs that had already been administered in the past and had each failed", explained Dr Javier Corts, the Head of the Breast Cancer Programme at the VHIO and main author of this work. This not only offers new alternatives for patients with advanced tumours the most important aspect but also opens up a parallel dimension of new therapeutic options to the existing treatments, given that it offers numerous combinations between existing pharmacological treatments that not only boost each other but also counteract patients' resistance to them. "The study focused on HER2 positive breast cancer, although the concept could be applied to the treatment of other tumours", continued Dr Corts.

Breast tumours occur most frequently in Western women. In Spain alone, some 24,000 new cases are diagnosed each year, and it is calculated that one in every eight or nine women in this country will suffer from breast cancer. Although the many advances over recent years in screening, early diagnosis and treatments have dramatically reduced mortality from this disease, there are still breast tumours whose biological characteristics make them more aggressive. Around 15% of breast tumours are HER2 positive and fall into this category. Moreover, they tend to affect younger women. In spite of the fact that this group has benefited tremendously from specific biological therapies targeted at this subtype (monoclonal antibodies), many tumours continue to advance and metastasize. "When a patient with this breast cancer subtype stops responding to the initial drug and the disease progresses, a second drug is administered. It may be that the response to these two treatments is negligible or there may even be no response at all and the tumour continues to grow. If we then treat the patients with the two drugs in combination, even though they ceased to function individually, what we have found is that almost 50% of the tumours responded to this combination and did so very positively, showing a clear improvement or keeping the disease stable for a considerable period of time", concluded Dr Corts.

In the fight against cancer, the combination of treatments is highly common practice. However, the concept described is different: it is not about seeing the results of combining drug A with drug B, but, when A fails to work, B is administered, and if this also fails we return to the starting point and initiate treatment with a combination of the two (A + B). This strategy could offer an unprecedented key to multiplying treatment options.

In the specific case of this study, we administered trastuzumab (the first-choice treatment for HER2 positive breast cancer); when the tumour continued growing we used pertuzumab (currently pending approval) and when the cancer continued to progress we administered the two together. "The results were very positive and highly informative for new studies", said Dr Corts.


'/>"/>

Contact: Amanda Wren
awren@vhio.net
34-695-207-886
Vall dHebron Institute of Oncology
Source:Eurekalert

Related medicine news :

1. Giant Eagle Pharmacy Free Antibiotics Program Surpasses $3 Million in Free Prescriptions
2. A Small Step For Today. A Giant Step For Tomorrow
3. “We've Got Balls” – Robin And The Giant Urge For Alternative Fuels
4. Giant Crayon Sweepstakes Giveaway Helps Businesses Increase Traffic for Back to School Promotions
5. Earth from space: Giant iceberg enters Nares Strait
6. A giant interneuron for sparse coding
7. Giant Weed Can Cause Blisters, Even Blindness
8. For Valentine's Day, Lifestyle Correspondent and Her Two Sets of Twins Show a Little Love Where Its Needed the Most
9. Reno Children With Disabilities Profit From a Little Known but Internationally Recognized Non-Profit Organization as it Quietly Crosses the $200,000.00 Mark in Service Investment Into the Reno Area
10. Secretary Clintons Approach to Development: Good Rhetoric, Little Action?
11. Experts Say Its Not So Bad to Go a Little Mad
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
Breaking Medicine Technology: